A retrospective cohort study of 9785 prostate cancer patients who received ADT showed that the incidence of cardiovascular events was significantly higher in the GnRH agonist treatment group when compared with the GnRH antagonist treatment group [71]. Here, GNRH1 is linked to prostate carcinoma.